C-JNNGAI drug discovery, machine learning, digital biology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Advance wholly owned internal drug programs in immunology toward clinical development.
AI-first drug design using Isomorphic Labs' AI drug design engine across relevant modalities.
Series B funding announced to accelerate the in-house drug pipeline into the clinic.
Advance wholly owned internal drug programs in oncology toward clinical development.
AI-first drug design using Isomorphic Labs' AI drug design engine across relevant modalities.
Series B funding announced to accelerate the in-house drug pipeline into the clinic.
Develop and deploy a unified AI drug design engine to predict biomolecular interactions and accelerate drug discovery across therapeutic areas and drug modalities.
Machine learning and AI drug design models building on and beyond AlphaFold, applied to small molecules, biologics, and biomolecular interaction prediction.
Series B funding announced to develop and deploy IsoDDE and accelerate in-house drug pipeline toward the clinic.
Reported accurate predictions of novel biomolecular interactions in a 2026 Zenodo record.
Advance wholly owned internal therapeutic programs discovered or designed using Isomorphic Labs' AI drug discovery platform into clinical development.
AI-enabled drug discovery using predictive and generative models to design molecules and anticipate drug performance.
Series B funding intended to help advance internal programs into clinical development.
Develop and deploy an AI drug design engine to transform and accelerate drug discovery, including designing novel molecules, anticipating drug performance, and supporting advancement of internal programs toward clinical development.
Frontier AI and machine learning platform building on AlphaFold 3 and related predictive/generative models for biomolecular structure, interaction prediction, and drug design.
Series B funding announced to develop and deploy IsoDDE and accelerate the in-house pipeline into the clinic.
Predict joint structures of biomolecular complexes across proteins, nucleic acids, small molecules, ions, and modified residues to support drug discovery and design.
Diffusion-based deep learning architecture for unified biomolecular structure and interaction prediction.
Published Nature paper reporting AlphaFold 3 accuracy across protein-ligand, protein-nucleic acid, and antibody-antigen prediction tasks.
Reported substantially improved accuracy versus previous specialized tools, including protein-ligand interactions compared with docking tools, protein-nucleic acid interactions, and antibody-antigen prediction compared with AlphaFold-Multimer v.2.3.
Predict structures and interactions of biomolecules to support AI-first drug discovery.
AI structure prediction model for biomolecular interactions.
Publication of AlphaFold 3 biomolecular interaction prediction results in Nature in 2024.
The supplied publication title reports accurate structure prediction of biomolecular interactions with AlphaFold 3.
Discover small-molecule drug candidates for undisclosed targets in partnership with Eli Lilly.
Use AlphaFold-enabled AI drug discovery to identify small molecules against undisclosed targets.
Partnership signed in January 2024, described as part of agreements worth up to nearly $3 billion combined with Eli Lilly and Novartis.
Use Isomorphic Labs' AlphaFold-enabled AI platform to discover small molecules for undisclosed Eli Lilly targets.
AI-assisted small-molecule discovery using AlphaFold-related models for undisclosed therapeutic targets.
Collaboration announced in January 2024 as part of pharma partnerships worth up to nearly $3 billion combined with Eli Lilly and Novartis.
Discover small-molecule drug candidates for undisclosed targets in partnership with Novartis.
Use AlphaFold-enabled AI drug discovery to identify small molecules against undisclosed targets.
Partnership signed in January 2024, described as part of agreements worth up to nearly $3 billion combined with Eli Lilly and Novartis.
Use Isomorphic Labs' AlphaFold-enabled AI platform to discover small molecules for undisclosed Novartis targets.
AI-assisted small-molecule discovery using AlphaFold-related models for undisclosed therapeutic targets.
Collaboration announced in January 2024 as part of pharma partnerships worth up to nearly $3 billion combined with Eli Lilly and Novartis.